Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4188-4196

  Demetri, George D ^a   Chawla, Sant P ^a   Von Mehren, Margaret ^a   Ritch, Paul ^a   Baker, Laurence H ^a   Blay, Jean Y ^a   Hande, Kenneth R ^a   Keohan, Mary L ^a   Samuels, Brian L ^a   Schuetze, Scott ^a   Lebedinsky, Claudia ^a   Elsayed, Yusri A ^a   Izquierdo, Miguel A ^a   Gómez, Javier ^a   Park, Youn C ^a   Le Cesne, Axel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC ANTIBIOTIC; TETRAHYDROISOQUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; JAUNDICE; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; AUSTRALIA; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; EUROPE; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; NORTH AMERICA; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TIME; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; AUSTRALIA; DIOXOLES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; NORTH AMERICA; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 70249101414     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.0088     Document Type: Article

References (33)

1. Skubitz KM, D'Adamo DR: Sarcoma. Mayo Clin Proc 82:1409-1432, 2007
2. Bramwell VH, Anderson D, Charette ML: Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev:CD003293, 2003
3. Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
4. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocytemacrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676-2684, 2000
5. Jelic S, Kovcin V, Milanovic N, et al: Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 33:220-225, 1997
6. van Oosterom AT, Mouridsen HT, Nielsen OS, et al: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406, 2002
7. Nielsen OS, Judson I, van Hoesel Q, et al: Effect of high-dose ifosfamide in advanced soft tissue sarcomas: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67, 2000
8. Buesa JM, Lopez-Pousa A, Martin J, et al: Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 9:871-876, 1998
9. Keizer HJ, Crowther D, Nielsen OS, et al: EORTC Group phase II study of oral etoposide for pretreated soft tissue sarcoma. Sarcoma 1:99-101, 1997
10. Carter NJ, Keam SJ: Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67:2257-2276, 2007
11. Garcia-Carbonero R, Supko JG, Manola J, et al: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480-1490, 2004
12. Le Cesne A, Blay JY, Judson I, et al: Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576-584, 2005
13. Yovine A, Riofrio M, Blay JY, et al: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890-899, 2004
14. Le Cesne A, Misset JL, Demetri G, et al: Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (STS): Results from a pooled analysis of three pivotal phase II clinical trials (P2CT) and safety profile of a 24h infusion schedule. Eur J Cancer 37:S34, 2001 (suppl 6: abstr 114)
15. Krasner CN, McMeekin DS, Chan S, et al: A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97: 1618-1624, 2007
16. Verweij J: Other endpoints in screening studies for soft tissue sarcomas. Oncologist 13:27-31, 2008 (suppl 2)
17. Schuetze SM, Baker LH, Benjamin RS, et al: Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 13:32-40, 2008 (suppl 2)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Wang SK, Tsiatis AA: Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 43:193-199, 1987
20. Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4:1079-1086, 1998
21. Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21:343-359, 2000
22. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
23. Clark MA, Fisher C, Judson I, et al: Soft-tissue sarcomas in adults. N Engl J Med 353:701-711, 2005
24. Wall N, Starkhammar H: Chemotherapy of soft tissue sarcoma: A clinical evaluation of treatment over ten years. Acta Oncol 42:55-61, 2003
25. Schoffski P, Wolter P, Clement P, et al: Trabectedin (ET-743): Evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 3:381-392, 2007
26. Garcia-Carbonero R, Supko JG, Maki RG, et al: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484-5492, 2005
27. Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of docetaxel versus doxorubicin in firstand second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2081-2086, 2000
28. Le Cesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995
29. Frustaci S, Foladore S, Buonadonna A, et al: Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 4:669-672, 1993
30. Palumbo R, Neumaier C, Cosso M, et al: Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: A phase II study. Eur J Cancer 35:66-72, 1999
31. Reichardt P, Tilgner J, Hohenberger P, et al: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 16:1438-1443, 1998
32. Spira AI, Ettinger DS: The use of chemotherapy in soft-tissue sarcomas. Oncologist 7:348-359, 2002
33. Minotti G, Menna P, Salvatorelli E, et al: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229, 2004